MCENANY PATRICK J sold (to issuer) $131.4M of CPRX
MCENANY PATRICK J sold (to issuer) 4,171,559 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($131.40M total) on 2026-07-15.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces the director’s holdings to zero and may influence short-term sentiment, but it does not introduce new operational or financial guidance.
Market read
Traders may monitor CPRX for sentiment follow-through, but the filing alone is unlikely to drive a durable repricing without additional catalysts.
What to watch
No 10b5-1 plan is cited, but the filing does not explain motivation; traders should avoid over-interpreting without corroborating news (earnings, guidance, trial updates).
Background
The article is an SEC Form 4 insider transaction disclosure for Catalyst Pharmaceuticals, Inc. (CPRX).
Ticker impact
Catalyst Pharmaceuticals director Patrick J. McEnany sold 4,171,559 shares to the issuer at $31.50 on 2026-07-15, totaling $131.4M.
Likely limited immediate impact; any effect is more sentiment-driven than thesis-changing.
The filing discloses transaction size, price, and post-transaction holdings (0 shares), but provides no new company performance, guidance, or regulatory/clinical catalyst.
Market effects
No direct sector read-across; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
A sale to the issuer can be routine (for example, buyback participation or structured liquidity) and may not reflect bearish fundamentals.
Key entities
- issuerCATALYST PHARMACEUTICALS, INC.
CPRX, the company whose director transaction is disclosed.
- insiderMCENANY PATRICK J
Director who sold 4,171,559 shares to the issuer at $31.50.